ATE247953T1 - Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure - Google Patents

Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure

Info

Publication number: ATE247953T1
Authority: AT; Austria
Prior art keywords: isoquercetin; ascorbic acid; delayed; products containing; medicinal products
Prior art date: 1999-03-16

Application number

AT00910786T

Other languages

English (en)

Inventor

Herwig Buchholz

Jerzy D Meduski

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-16

Filing date

2000-03-08

Publication date

2003-09-15

2000-03-08 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2003-09-15 Application granted granted Critical

2003-09-15 Publication of ATE247953T1 publication Critical patent/ATE247953T1/de

Links

CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 4
OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 title abstract 2
FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 title abstract 2
OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 title abstract 2
OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 title abstract 2
229960005070 ascorbic acid Drugs 0.000 title 1
235000010323 ascorbic acid Nutrition 0.000 title 1
239000011668 ascorbic acid Substances 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
239000000203 mixture Substances 0.000 abstract 2
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
SXZYCXMUPBBULW-SKNVOMKLSA-N L-gulono-1,4-lactone Chemical compound OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O SXZYCXMUPBBULW-SKNVOMKLSA-N 0.000 abstract 1
229930003268 Vitamin C Natural products 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000007074 memory dysfunction Effects 0.000 abstract 1
239000004090 neuroprotective agent Substances 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1
235000019154 vitamin C Nutrition 0.000 abstract 1
239000011718 vitamin C Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

AT00910786T 1999-03-16 2000-03-08 Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure ATE247953T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12486399P	1999-03-16	1999-03-16
PCT/EP2000/002008 WO2000054754A2 (en)	1999-03-16	2000-03-08	Composition comprising isoquercetin and ascorbic acid in a sustained release form

Publications (1)

Publication Number	Publication Date
ATE247953T1 true ATE247953T1 (de)	2003-09-15

Family

ID=22417166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00910786T ATE247953T1 (de)	1999-03-16	2000-03-08	Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure

Country Status (10)

Country	Link
US (1)	US6491948B1 (de)
EP (1)	EP1161228B1 (de)
JP (1)	JP2003526619A (de)
AT (1)	ATE247953T1 (de)
AU (1)	AU3287200A (de)
CA (1)	CA2367387C (de)
DE (1)	DE60004797T2 (de)
DK (1)	DK1161228T3 (de)
ES (1)	ES2204531T3 (de)
WO (1)	WO2000054754A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19809304A1 (de) *	1998-03-05	1999-09-09	Merck Patent Gmbh	Formulierungen mit antiviraler Wirkung
CN1477958A (zh) *	2000-10-31	2004-02-25	高露洁-棕榄公司	组合物及方法
ATE424187T1 (de) *	2002-07-15	2009-03-15	Alcon Inc	Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
CA2587406A1 (en) *	2004-11-16	2006-05-26	Limerick Neurosciences, Inc.	Methods and compositions for treating pain
US20070087977A1 (en) *	2004-11-16	2007-04-19	Wendye Robbins	Methods and compositions for treating pain
JP2006160668A (ja) *	2004-12-08	2006-06-22	Sanei Gen Ffi Inc	過酸化脂質生成抑制剤
EP2040708B1 (de) *	2006-07-17	2018-03-14	Thomas Christian Lines	Quercetinhaltige zusammensetzungen
US7745487B2 (en) *	2006-07-17	2010-06-29	Quercegen Pharma Llc	Method for enhancing physical performance or immune system recovery from intense physical excercise with quercetin-containing compositions
EP2200605A4 (de) *	2007-10-01	2011-03-23	Quercegen Pharma Llc	Verfahren zur stabilisierung von quercetin
EP2231150A4 (de)	2008-01-18	2011-06-22	Thomas Christian Lines	Verfahren zur suchtbehandlung mit quercetinhaltigen zusammensetzungen
US8574619B2 (en) *	2008-09-05	2013-11-05	Quercegen Pharmaceuticals, LLC	Reducing cholesterol levels with combined use of quercetin and statin
US8034363B2 (en) *	2008-12-11	2011-10-11	Advanced Technologies And Regenerative Medicine, Llc.	Sustained release systems of ascorbic acid phosphate
TWI660680B (zh)	2012-11-26	2019-06-01	美商通路實業集團國際公司	抗氧化膳食增補劑及其相關方法
JP6175048B2 (ja) *	2013-12-27	2017-08-02	花王株式会社	容器詰飲料
HUE045054T2 (hu)	2014-12-23	2019-12-30	Hermes Arzneimittel Gmbh	Késleltetve kibocsátott hatóanyagot tartalmazó direkt granulátum
WO2017096049A1 (en)	2015-12-03	2017-06-08	The University Of North Carolina At Pembroke	Materials for cathepsin b enhancement and methods of use
TWI761672B (zh)	2018-04-23	2022-04-21	日商阿爾卑斯藥品工業股份有限公司	O-醣苷基類黃酮之組成物
US11872241B2 (en)	2018-11-30	2024-01-16	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for reducing major thrombotic events in cancer patients
US10617705B1 (en) *	2019-01-24	2020-04-14	Alps Pharmaceutical Ind. Co., Ltd.	Isoquercitrin compositions
US10918654B1 (en)	2019-09-23	2021-02-16	Alps Pharmaceutical Ind. Co., Ltd.	Rutin compositions
US11110109B2 (en)	2019-10-22	2021-09-07	Alps Pharmaceutical Ind. Co., Ltd.	Water soluble O-glycosyl flavonoid compositions and methods for preparing same
CN113712982B (zh) *	2021-09-13	2022-12-06	广东金骏康生物技术有限公司	一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5944327A (ja) *	1982-09-06	1984-03-12	Taiyo Kagaku Kk	Ｌ−アスコルビン酸およびその塩類の安定化法
JP2514201B2 (ja) *	1987-04-16	1996-07-10	横浜油脂工業株式会社	微粉状ｌ−アスコルビン酸被覆物の製造方法
JPH01296953A (ja) *	1988-05-24	1989-11-30	Freunt Ind Co Ltd	ビタミンｃ組成物、それを添加した飼料およびその製造方法
JP2997303B2 (ja) *	1990-08-19	2000-01-11	三栄源エフ・エフ・アイ株式会社	褐変防止剤
JP3016835B2 (ja) *	1990-08-19	2000-03-06	三栄源エフ・エフ・アイ株式会社	アスコルビン酸の褐変防止方法
JPH06199693A (ja) *	1992-03-06	1994-07-19	Yunie:Kk	虚血性疾患改善治療剤
JPH06199690A (ja) *	1992-03-06	1994-07-19	Yunie:Kk	脳代謝促進・脳機能改善剤
JPH0745402B2 (ja) *	1993-03-23	1995-05-17	信和薬品株式会社	持続性アスコルビン酸製剤
JPH07196523A (ja) *	1994-01-07	1995-08-01	Oomiya Yakugyo Kk	ケルセチン配糖体を含有する内用液剤
US5972995A (en) *	1997-10-16	1999-10-26	Children's Hospital Medical Center Of Northern California	Compositions and methods for cystic fibrosis therapy
US5972985A (en) *	1997-11-03	1999-10-26	Cytos Pharmaceuticals, Llc	Histidine containing nutriceutical compositions

2000
- 2000-03-08 ES ES00910786T patent/ES2204531T3/es not_active Expired - Lifetime
- 2000-03-08 DK DK00910786T patent/DK1161228T3/da active
- 2000-03-08 AT AT00910786T patent/ATE247953T1/de not_active IP Right Cessation
- 2000-03-08 EP EP00910786A patent/EP1161228B1/de not_active Expired - Lifetime
- 2000-03-08 CA CA002367387A patent/CA2367387C/en not_active Expired - Fee Related
- 2000-03-08 AU AU32872/00A patent/AU3287200A/en not_active Abandoned
- 2000-03-08 JP JP2000604830A patent/JP2003526619A/ja active Pending
- 2000-03-08 WO PCT/EP2000/002008 patent/WO2000054754A2/en not_active Ceased
- 2000-03-08 DE DE60004797T patent/DE60004797T2/de not_active Expired - Lifetime
- 2000-03-15 US US09/525,457 patent/US6491948B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2003526619A (ja)	2003-09-09
CA2367387C (en)	2009-06-23
CA2367387A1 (en)	2000-09-21
WO2000054754A3 (en)	2000-12-28
AU3287200A (en)	2000-10-04
DE60004797T2 (de)	2004-06-17
DE60004797D1 (de)	2003-10-02
DK1161228T3 (da)	2003-11-24
US6491948B1 (en)	2002-12-10
EP1161228B1 (de)	2003-08-27
EP1161228A2 (de)	2001-12-12
ES2204531T3 (es)	2004-05-01
WO2000054754A2 (en)	2000-09-21

Legal Events

Date	Code	Title	Description
2004-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE247953T1 (de)	2003-09-15	Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
EP1283054A4 (de)	2006-04-12	Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
AU2002218167A1 (en)	2002-03-26	N-phenyl-2-pyrimidine-amine derivatives
TR200500745T2 (tr)	2005-05-23	Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
BG66093B1 (bg)	2011-04-29	Състави с контролирано освобождаване, съдържащи нимесулид
ATE507246T1 (de)	2011-05-15	Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel
DE60001546D1 (de)	2003-04-10	Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE602004022761D1 (de)	2009-10-08	Vitamine B3 und Vitamine C enthaltende Peelingzusammensetzung
DK1289517T3 (da)	2006-04-03	Farmaceutiske sammensætninger indeholdende cannabidiolderivater
TW200630123A (en)	2006-09-01	Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
WO2005000232A3 (en)	2005-04-28	Six membered amino-amide derivatives as angiogenesis inhibitors
DE69923336D1 (de)	2005-02-24	Oral anzuwendende buprenorphinhaltige arzneimittel
DE69006202D1 (de)	1994-03-03	Verbesserungen betreffend die Verabreichung pharmazeutischer Mittel.
TNSN07203A1 (en)	2008-11-21	Pharmaceutical compositions for the treatment of cellulite
ATE286894T1 (de)	2005-01-15	2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
HUP0600084A2 (en)	2006-06-28	Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
ATE286893T1 (de)	2005-01-15	2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
SE0001916D0 (sv)	2000-05-23	Novel formulation
MY133230A (en)	2007-10-31	Combination of no synthase inhibitor(s) and metabolic antioxidant(s)
ATE347886T1 (de)	2007-01-15	Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
PL355113A1 (en)	2004-04-05	Novel fusidic acid derivatives
WO2002070537A3 (en)	2002-11-07	Fusidic acid derivatives
EP2266566A3 (de)	2011-01-12	Nicotinamid Derivate und ihrer Verwendung als Therapeutika
SE9901079D0 (sv)	1999-03-23	Novel compounds
EP1595879A3 (de)	2010-01-27	Alkoxy substituierte Benzimidazolverbindungen , diese enthaltende Arzneimittel und ihre Vervendung